Digital mammo plus breast MRI proves clinically beneficial, but not cost-effective
Digital mammography plus MRI is the most clinically effective strategy for screening women carrying a genetic mutation known to increase the risk for breast cancer. However, unless the cost of breast MRI decreases substantially, the modality doesn’t translate as cost-effective, according to a study presented on Tuesday at the RSNA 2009 meeting.
Digital mammography plus MRI is the most clinically effective strategy for screening women carrying a genetic mutation known to increase the risk for breast cancer. However, unless the cost of breast MRI decreases substantially, the modality doesn't translate as cost-effective, according to a study presented on Tuesday at the RSNA 2009 meeting.
Women carrying the BRCA1/BRCA2 genes are 60% to 70% more likely than other women to develop breast cancer. The American Cancer Society recommends those women get screened using breast MRI, but Dr. Janie Lee, a staff radiologist at Massachusetts General Hospital in Boston, said the test doesn't measure up in terms of cost-effectiveness.
Lee and colleagues compared four annual screening strategies with clinical surveillance without imaging for a cohort of 25-year-old BRCA1 mutation carriers. Using a Markov Monte Carlo model, the researchers measured film mammography, digital mammography, film mammography plus MRI, and digital mammography plus MRI.
Digital mammography alone was more effective than film mammography in terms of quality-adjusted life years, or the value for money for a medical intervention. Digital mammography resulted in 44.54 QALYs versus 44.38 for film-screen. Digital mammography plus MRI resulted in 44.63 QALYs versus 44.57 for film-screen plus MRI.
Digital mammography plus MRI was the most effective examination but also had the highest lifetime costs. The incremental cost of adding MRI to digital mammography was $136,583 per QALY gained.
Sensitivity analysis demonstrated the incremental cost-effectiveness ratio for digital mammography and MRI would come down below $100,000 per QALY only if the cost of breast MRI decreased, Lee said.
Annual MRI and digital mammography screening became more cost-effective when the cost of an MRI decreased from $604 to $402, or when mutation penetrance increased from 65% to 71%, she said.
The research was supported in part by grants from the National Institutes of Health.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
